BioAtla (NASDAQ:BCAB) Announces Quarterly Earnings Results

BioAtla (NASDAQ:BCAB) announced its quarterly earnings data on Friday. The company reported ($4.22) EPS for the quarter, topping analysts’ consensus estimates of ($10.00) by $5.78, FiscalAI reports.

BioAtla Stock Performance

Shares of BCAB stock traded down $0.10 during mid-day trading on Friday, reaching $4.27. The company’s stock had a trading volume of 27,443 shares, compared to its average volume of 45,987. BioAtla has a 1-year low of $3.92 and a 1-year high of $71.50. The company has a market cap of $7.08 million, a P/E ratio of -0.08 and a beta of 0.81. The firm’s 50-day moving average is $6.25 and its two-hundred day moving average is $19.75.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded BioAtla to a “hold” rating in a research report on Saturday, April 11th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $200.00.

Institutional Investors Weigh In On BioAtla

Several large investors have recently modified their holdings of BCAB. Woodline Partners LP bought a new stake in shares of BioAtla in the 1st quarter valued at approximately $26,000. ADAR1 Capital Management LLC bought a new stake in shares of BioAtla in the 4th quarter valued at approximately $104,000. Susquehanna International Group LLP boosted its stake in shares of BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after purchasing an additional 123,597 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of BioAtla in the 3rd quarter valued at $235,000. 77.23% of the stock is currently owned by institutional investors.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.